June 12, 2020 -- Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European facility.
Yescarta (axicabtagene ciloleucel) was the first chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphoma and primary mediastinal large B-cell lymphoma. The drug is similarly approved in the European Union.
Kite's European cell therapy manufacturing facility, located outside of Amsterdam. Image courtesy of Kite.
Kite has nearly 90 treatment centers in 16 countries across Europe and Israel. The new European facility with a central location right outside of Amsterdam will reduce the delivery time to and from treatment centers. The facility has the capacity to produce therapies for up to 4,000 patients per year.
Copyright © 2020 scienceboard.net